DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro i...
Guardado en:
Autores principales: | Adriana S Azevedo, Anna M Y Yamamura, Marcos S Freire, Gisela F Trindade, Myrna Bonaldo, Ricardo Galler, Ada M B Alves |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b93119332faf4a7aa16d1ebb630c57ff |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Toshifumi Imagawa, et al.
Publicado: (2021) -
Sulfated Escherichia coli K5 polysaccharide derivatives inhibit dengue virus infection of human microvascular endothelial cells by interacting with the viral envelope protein E domain III.
por: Peter Vervaeke, et al.
Publicado: (2013) -
Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies
por: Emily N. Gallichotte, et al.
Publicado: (2019) -
Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein
por: Kiven Kumar, et al.
Publicado: (2021) -
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
por: J. A. Swanstrom, et al.
Publicado: (2016)